This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce.
This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials.
This means that IscB base editors might be easier to package inside of AAVs, which can only store 4,700 bases of DNA for gene therapies. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials.
Even small changes in the Parliament’s composition could have an impact on ongoing legislative discussions, such as the revisions to the pharma reform package. The current European Parliament and Commission have confirmed their position on the pharma package, but the European Council is still working on its negotiation position.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
A live demo is available online, but “it chews through OpenAI credits,” Patel says. There’s a live demo available online. “Right now, it can only make one protein at a time,” Gershon says, simply because the demo has limited compute resources. “Every query is like $2.” A Mycoplasma cell.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content